A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

Brief summary (registry, in English)

This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 359
• From 11 Jun 2026 to the primary completion date, 18 Sept 2028
• 175 sites in 23 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (175)

Sites in registry order. Pick your city on the disease page to sort them by distance.